

Approved for  
12.0 AMA PRA Category 1 Credits™

PROUDLY HOSTED BY



11<sup>th</sup>  
2024  
ANNUAL



Spring To Life™

The graphic for the "Spring To Life" logo shows a green silhouette of a person jumping joyfully. Several red blood cells are scattered around the figure, with some appearing to be in motion, suggesting vitality and health.

## Focus On Genitourinary and Gynecologic Cancers

May 2-3, 2024 • Albany Capital Center • Albany, NY

*a CME-accredited, 2-day educational conference*

Hosted By



Accredited by



Conference Collaborator



Organized By





# Spring To Life™

Dear Healthcare Professional Colleagues:

On behalf of New York Oncology Hematology, we welcome you to our 11th annual Spring to Life Conference. Our focus this year is on Genitourinary and Gynecologic Cancers 2024.

Over these 2 days, we look forward to a robust agenda across these malignancies, in which we continue to see advances in our science, research, developed therapeutics and changing paradigms of treatment to meaningfully impact both the longevity and quality of lives of our patients. We also emphasize the important aspects of screening and prevention and other health and supportive care that impact these outcomes and at the core of our holistic care of the people we serve.

Spring to Life emphasizes the vital collaboration of community-based cancer care with academic research and expertise that advance our knowledge and mutual care of cancer patients. Once again, we primarily draw on the rich thought leadership that exists in our region and we thank our faculty speakers for joining with us this year.

I want to thank Dr. David Shafer and Dr. Heidi Godoy, the Moderators for our sessions this year and who joined me and our conference organizer MyMedEd to bring this all together. An important additional thank you to our conference sponsors and exhibitors who help make this event possible year after year. Please take time to visit and engage with the Exhibitors. We all work together to advance the improvement of all outcomes in those living with and surviving cancer.

Lastly, thank you for attending this 11th annual Spring to Life Conference! Enjoy the bloom of early Spring in Albany and surrounding areas.

Sincerely,

Ira Zackon, M.D.

Hematologist, New York Oncology Hematology and Spring to Life Conference Chair  
Clinical Assistant Professor, Albany Medical College

# Thursday, May 2, 2024 - Genitourinary Cancers

## Educational Goal:

The Genitourinary Cancers program will bring together a world-renowned group of experts in the field of genitourinary oncology to present the latest clinical research data in this field.

## Target Audience:

The target audience for this conference is medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals, and other providers interested in the care of patients with cancer.

## Learning Objectives:

After participating in this activity, learners will be better able to:

1. Determine optimal surgical options for non-invasive and invasive urothelial cancers, renal cancers, and localized prostate cancer.
2. Evaluate systemic therapy options, including new targeted therapies, for non-invasive and invasive urothelial cancers, renal cancers, prostate cancers, germ cell tumors, and testicular cancer.
3. Understand current radiation therapy management of localized prostate cancer.

ALBANY CAPITAL CENTER: LEVEL 2 - FOYER			
7:30 AM	4:00 PM	REGISTRATION AND CONFERENCE INFORMATION DESK	
ALBANY CAPITAL CENTER: LEVEL 2 – MULTIPURPOSE ROOM			
7:30 AM	9:00 AM	EXHIBITS AND BREAKFAST	
ALBANY CAPITAL CENTER: LEVEL 2 – PRE-FUNCTION SPACE			
9:00 AM	9:10 AM	Introduction	Co-Chairs & Moderators: Ira Zackon, MD (NYOH) and David Shaffer, MD (AMC)
9:10 AM	9:50 AM	Surgery for Urothelial Cancer	Timothy F. Donahue, MD (MSKCC)
9:50 AM	10:30 AM	Systemic Therapy of Urothelial Cancer	Gopa Iyer, MD (MSKCC)
10:30 AM	11:10 AM	Surgery for Kidney Cancer	A. Ari Hakimi, MD (MSKCC)
11:10 AM	11:50 AM	Systemic Therapy of Renal Cancer	Martin H. Voss, MD (MSKCC)
ALBANY CAPITAL CENTER: LEVEL 2 – MULTIPURPOSE ROOM			
11:50 AM	12:50 PM	EXHIBITS AND LUNCH	
ALBANY CAPITAL CENTER: LEVEL 1 – MEETING ROOM 1A			
11:50 AM	12:50 PM	Optional Non-CME Educational Presentation A Different Approach to Treat Metastatic Urothelial Cancer <small>THIS ACTIVITY IS SPONSORED BY: GILEAD</small>	Alan Tan, MD (RUSH)
ALBANY CAPITAL CENTER: LEVEL 2 – PRE-FUNCTION SPACE			
12:50 PM	1:30 PM	Surgery Of Prostate Cancer	Karim A. Touijer, MD (MSKCC)
1:30 PM	2:10 PM	Radiation of Prostate Cancer	Justin Juliano, MD (NYOH)
2:10 PM	2:50 PM	Androgen Receptor-Targeted Therapy in Prostate Cancer	Rahul Ravilla, MD (NYOH)
2:50 PM	3:30 PM	Therapy for Androgen-Insensitive Prostate Cancer	Susan Slovin, MD (MSKCC)
3:30 PM	4:10 PM	Treatment of Refractory Germ Cell Tumors	Darren R. Feldman, MD (MSKCC)
4:10 PM	4:15 PM	Concluding Remarks	Co-Chairs & Moderators: Ira Zackon, MD (NYOH) and David Shaffer, MD (AMC)
RENAISSANCE ALBANY HOTEL: 2nd Floor, THE SHELF		<ul style="list-style-type: none"> <li>• Go to the Renaissance Parking Garage on Level 1 from Albany Capital Center</li> <li>• Take the Parking Garage Elevator to the hotel's Lobby Level</li> <li>• Proceed to the Green Marble Stairs or Lobby Elevator up to the 2nd Floor</li> <li>• THE SHELF is immediately to the left</li> </ul>	
4:30 PM	6:00PM	NETWORKING SOCIAL HOUR	ALL FACULTY AND ATTENDEES



## Friday, May 3, 2024 – Gynecologic Cancers

### Educational Goal:

The Gynecologic Cancers program will bring together thought leaders in the field of gynecology and gynecologic oncology to present the most up-to-date clinical research and data that is emerging in the field.

### Target Audience:


The target audience for this conference is medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals, and other providers interested in the care of patients with cancer.

### Learning Objectives:

After participating in this activity, learners will be better able to:


1. Determine the optimal integration of combined modality systemic, intraperitoneal and surgical debulking management of ovarian cancer
2. Understand the use of systemic immunotherapy, as well as individualized decisions on pelvic radiation therapy in advanced endometrial cancer
3. Update current screening and prevention in cervical, endometrial, and ovarian cancers, including obesity management.

ALBANY CAPITAL CENTER: LEVEL 2 - FOYER			
7:00 AM	4:00 PM	REGISTRATION AND CONFERENCE INFORMATION DESK	
LEVEL 2 – MULTIPURPOSE ROOM			
7:00 AM	8:00 AM	EXHIBITS AND BREAKFAST	
ALBANY CAPITAL CENTER: LEVEL 2 – PRE-FUNCTION SPACE			
8:00 AM	8:05 AM	Introduction	Co-Chairs & Moderators: Ira Zackon, MD (NYOH) and Dr. Heidi Godoy, MD (NYOH)
8:05 AM	8:35 AM	History of Gyn Oncology	Shashi Lele, MD (Roswell Park)
8:35 AM	8:55 AM	Management of Pap Smear of HPV Vaccinations	Danielle Rooney, MD (Community Care Physicians)
8:55 AM	9:25 AM	Updates in Cervical Cancer: Break Down Surgery, Chemo, and IO Updates	Thomas Krivak, MD (Allegheny Health Network)
ALBANY CAPITAL CENTER - LEVEL 2 – MULTIPURPOSE ROOM			
9:25 AM	9:40 AM	EXHIBITOR BREAK	
ALBANY CAPITAL CENTER: LEVEL 2 – PRE-FUNCTION SPACE			
9:40 AM	10:00 AM	Management of Ovarian Cysts for the Generalist	James Izzano, MD (St. Mary's Hospital Amsterdam)
10:00 AM	10:30 AM	Hyperthermic Intraperitoneal Chemotherapy: Emerging Standard of Care	Olga Filippova, MD (Lenox Hill Hospital)
10:30 AM	11:00 AM	Neoadjuvant Induction Chemotherapy vs Up Front Debulking Ovarian Cancer	Joshua Kesterson, MD (UPMC)



ALBANY CAPITAL CENTER - LEVEL 2 – MULTIPURPOSE ROOM			
11:00 AM	12:00 PM	EXHIBITS AND LUNCH	
ALBANY CAPITAL CENTER: LEVEL 2 – PRE-FUNCTION SPACE			
12:00 PM	12:40 PM	KEYNOTE: Role of IO Therapy in Endometrial Cancer	Susana Campos, MD (Dana Farber)
12:40 PM	1:10 PM	Endometrial Cancer Updates: Who Understands the New Staging?	Mark Shahin, MD (Alliance Health)
1:10 PM	1:40 PM	Adjuvant Radiotherapy in Endometrial Cancer	Justin Juliano, MD (NYOH)
1:40 PM	2:10 PM	Vaginal health: Intraoperative Considerations and Beyond	Rebecca Phaeton, MD (GSK)
ALBANY CAPITAL CENTER - LEVEL 2 – MULTIPURPOSE ROOM			
2:10 PM	2:25 PM	EXHIBITOR BREAK	
ALBANY CAPITAL CENTER: LEVEL 2 – PRE-FUNCTION SPACE			
2:25 PM	2:45 PM	Palliative Care in Gyn Oncology Cancers	Colleen Murray, NP (NYOH)
2:45 PM	3:05 PM	Management of Obesity: Role of GLP-1 Receptor Agonist in Gyn Patients	Mary Paquet, NP (Elevate Health)
3:05 PM	3:35 PM	Updates in Biomarkers in Gyn Cancer	Gary Altwerger, MD (Yale)
3:35 PM	4:05 PM	Tumor Board	Melanie Hawver, MD (St. Peter's Health Partners) and Ellie Kolor, Student (Touro)
4:05 PM	4:15 PM	Concluding Remarks	Co-Chairs & Moderators: Ira Zackon, MD (NYOH) and Dr. Heidi Godoy, MD (NYOH)
RENAISSANCE ALBANY HOTEL: 2nd Floor, <b>HYLAND LIBRARY</b>		<ul style="list-style-type: none"> <li>• Go to the Renaissance Parking Garage on Level 1 from Albany Capital Center</li> <li>• Take the Parking Garage Elevator to the hotel's Lobby Level</li> <li>• Proceed to the Green Marble Stairs or Lobby Elevator up to the 2nd Floor</li> <li>• The <b>HYLAND LIBRARY</b> is immediately to the right</li> </ul>	
4:30 PM	6:00 PM	NETWORKING SOCIAL HOUR	ALL FACULTY AND ATTENDEES





## FACULTY

### CONFERENCE COURSE CHAIR



**Ira Zackon, MD**  
**New York Oncology Hematology,**  
**Immediate Past President**  
**Hematologist/Medical Oncologist**  
**NYOH Albany Medical Center**  
**Clinical Assistant Professor**  
**Albany Medical College**  
**Albany, NY**

Ira Zackon, MD, is a Hematologist/ Oncologist, former Stem Cell Transplant Program Director, and immediate past President of New York Oncology Hematology, PC (NYOH). He is an Assistant Clinical Professor at Albany Medical College in Albany, New York. After earning a medical degree in 1986 from McGill University in Montreal, Canada, he completed an internship and residency in Internal Medicine at Royal Victoria Hospital in Montreal in 1989. Dr. Zackon completed Hematology/Medical Oncology fellowships at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (1990-1992), and Northwestern University Medical Center, Chicago, Illinois (1992-1994). At NYOH, Dr. Zackon has further developed the practice's autologous stem cell transplant program, expanded collaborative care for allogeneic bone marrow transplant patients at NYOH with regional transplant centers, and focused NYOH participation in research trials in the hematologic malignancies through the US Oncology Network and the Blood Cancer Research Partnership in association with the Dana-Farber Cancer Institute in Boston, Massachusetts. He continues to practice with NYOH and is a part-time Senior Medical Director for Real-World Data Research with Ontada.

### GENITOURINARY CANCERS CHAIR



**David R. Shaffer, MD**  
**Medical Oncologist NYOH, retired**  
**President Board of Directors, NYOH**  
**Community Cancer Foundation**  
**Albany, NY**

Dr. David R. Shaffer is a physician and scholar who specializes in medical oncology at New York Oncology Hematology,

PC, Albany. He earned his MD and PhD in Microbiology and Immunology from the University of North Carolina Chapel Hill School of Medicine. Dr. Shaffer completed his medical internship and residency at Barnes-Jewish Hospital in St. Louis, Missouri, followed by a clinical fellowship at Memorial Sloan-Kettering Cancer Center in New York. His academic career includes positions at Albany Medical Center and Memorial Sloan-Kettering Cancer Center.

Dr. Shaffer is also involved in research, having led various projects on prostate cancer and participated in major clinical trials. His research has resulted in numerous peer-reviewed publications. A member of prestigious medical societies and the recipient of numerous awards, Dr. Shaffer's work has contributed to the field of oncology, demonstrating his dedication to advancing medical oncology and improving patient care.

### GYNECOLOGIC CANCERS CHAIR



**Heidi Godoy, DO**  
**Gynecologic Oncologist**  
**New York Oncology Hematology**  
**Albany, NY**

Heidi E. Godoy, D.O. joined New York Oncology Hematology (NYOH) on December 1, 2021, expanding our service line offerings at our Albany Cancer Center to include gynecologic oncology and surgery. Dr. Godoy specializes in medically and surgically treating cancers of female reproductive organs, including ovarian, endometrial, and cervical cancers.

"Dr. Godoy joining our practice allows us to increase access to care to our patients and the Capital Region community. Her surgical experience and specialization in this area of oncology will give us additional insight into the latest treatments, technologies, therapies, and precision medicine for our female patients with gynecologic cancers. We look forward to growing and expanding this service line under her leadership," said Todd Doyle, MD, NYOH radiation oncologist and practice president.

NYOH anticipates expanding gynecologic oncology and surgery to our Hudson Cancer Center in early 2022. Dr. Godoy is board-certified in obstetrics and gynecology, gynecology

oncology and robotics. She completed her fellowship at Roswell Park Cancer Institute in gynecologic oncology. Prior to NYOH, she spent the past nine years at Women's Cancer Care Associates as a gynecologic oncologist and surgeon. She is a member of several professional associations, including the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists.

## FACULTY PRESENTERS



**Gary Altwerger, MD**  
**Assistant Professor**  
**Division of Gynecologic Oncology**  
**Department of OB/GYN and**  
**Reproductive Sciences**  
**Yale University**  
**New Haven, CT**

Dr. Gary Altwerger is an Assistant Professor at the Yale University School of Medicine, specializing in Gynecologic Oncology. He earned his MD from the University at Buffalo School of Medicine and Biomedical Sciences in 2012. His professional journey includes roles at Yale-New Haven Hospital, where he completed his residency and fellowship.

Dr. Altwerger's career is distinguished by his impactful clinical and translational research contributions. His focus on DNA damage repair and the clinical applications of PARP inhibitors in ovarian cancer has significantly advanced the field. He has published extensively in peer-reviewed journals as a principal investigator on numerous clinical trials and research projects. His dedication extends to mentoring medical students, residents, and fellows, shaping the future of Gynecologic Oncology.

Dr. Altwerger is recognized nationally and internationally and has received multiple awards, including the Laxmi Baxi Award by the Society for Reproductive Investigation. At Yale, he holds the position of Assistant Director of Inpatient Gynecologic Oncology Services and Supervising Physician for Morbidity and Mortality in Gynecologic Oncology. He is extensively involved in developing innovative teaching tools and methods, such as surgical videos for educational purposes and AI instruction in surgery.



**Susana M. Campos, MD**  
**Assistant Professor of Medicine**  
**Dana-Farber Cancer Institute, Harvard**  
**Medical School**  
**Boston, MA**


Dr. Susana M. Campos is an esteemed Institute Physician in Medical Oncology at Dana-Farber Cancer Institute, Associate Physician in Medical Oncology at Brigham and Women's Hospital, and Assistant Professor of Medicine at Harvard Medical School. She received her medical degree from Georgetown University and further advanced her expertise with a Master of Public Health from Harvard T.H. Chan School of Public Health. Her extensive training includes residencies and fellowships at Harvard Medical School and Brigham and Women's Hospital.

Dr. Campos is a key figure in the field of gynecological oncology. She has a robust clinical role as an Institute Physician in Medical Oncology at Dana-Farber Cancer Institute. In this capacity, she oversees the treatment and management of patients with ovarian, endometrial, and cervical cancers. Her research is focused on the development and application of novel therapies for gynecological cancers, and she boasts an extensive portfolio of peer-reviewed publications on this topic. Notably, she holds influential positions in national committees such as the National Comprehensive Cancer Network, where she plays a pivotal role in shaping guidelines on the management of uterine and cervical cancers. Her leadership extends to teaching and mentoring roles, where she educates and guides gynecological oncology fellows, medical oncology residents, and junior physicians.



**Timothy Donahue, MD**  
**Associate Attending**  
**Department of Surgery**  
**Memorial Sloan Kettering Cancer**  
**Center**  
**New York, NY**

Dr. Timothy F. Donahue is a Urologic Oncologist at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York. He earned his MD from Boston University School of Medicine in 1995 and completed his General Surgery Internship and Urology Residency at the National Naval



Medical Center, Bethesda, MD. Dr. Donahue further obtained a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Donahue's extensive professional experience includes roles such as the Attending Urologist at the National Naval Medical Center, Associate Investigator at the Center for Prostate Disease Research, and Urologic Oncologist at Memorial Sloan Kettering Cancer Center, where he currently works.

His contributions to academia and clinical practice are distinguished by numerous teaching roles, significant clinical research, and various leadership positions in medical administration. Dr. Donahue is a respected speaker and educator, often presenting on topics such as prostate cancer and surgical techniques. His career is marked by a strong commitment to medical education, evidenced by his roles in several prestigious medical institutions and contributions to clinical research and professional development in urology.



**Darren R. Feldman, MD**  
**Section Head Germ Cell Cancer**  
**Associate Attending Physician**  
**Memorial Sloan Kettering Cancer**  
**Center**  
**New York, NY**

Dr. Darren R. Feldman is an Associate Professor of Medicine at Weill Cornell Medical College and an esteemed Associate Member at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. He earned his MD from the University of Maryland School of Medicine in 2001. His postdoctoral training includes an internship and residency in Internal Medicine, as well as fellowships in medical oncology and hematology at NYU School of Medicine and MSKCC. He specializes in Medical Oncology and Hematology, with a keen focus on genitourinary malignancies.

Dr. Feldman is recognized for his contributions to clinical trials and cancer research, particularly in testicular cancer. Dr. Feldman's roles at MSKCC and Weill Cornell extend beyond his clinical expertise. He is deeply committed to medical education and mentoring, having developed, and directed numerous courses and lectures focused on oncology education and clinical practice. His dedication to guiding the next generation of medical professionals is a testament to his passion and commitment.



**Olga T. Filippova, MD, MSc**  
**Attending, Gynecologic Oncology**  
**Department of Obstetrics and**  
**Gynecology**  
**Lenox Hill Hospital**  
**New York, NY**

Dr. Olga T. Filippova is a Gynecologic Oncologist at Lenox Hill Hospital in New York. She completed her BS/MD program in Biomedical Engineering with honors at Drexel University, followed by an MD from the same institution. Dr. Filippova honed her expertise in Obstetrics and Gynecology at Albany Medical Center and further specialized in Gynecologic Oncology during her fellowship at Memorial Sloan Kettering Cancer Center, where she also pursued a Master of Science in Clinical Epidemiology.

Her professional career includes roles as an attending physician at Albany Medical Center. Dr. Filippova is actively involved in cutting-edge research, with a particular focus on ovarian cancer, including clinical trials, surgical education, and geriatric oncology. She contributes to numerous publications and presentations, emphasizing her commitment to advancing gynecologic oncology.

A Fellow of the American College of Obstetricians and Gynecologists and a member of several professional societies, Dr. Filippova's contributions extend beyond clinical practice into significant research endeavors aimed at improving care for elderly cancer patients.



**Ari Hakimi, MD (pre-record)**  
**Associate Professor Department of**  
**Surgery, Urology Service**  
**Co-Leader Translational Kidney Cancer**  
**Program**  
**Memorial Sloan Kettering Cancer**  
**Center**  
**New York, NY**

Dr. Ari A. Hakimi is an Associate Member of the Department of Surgery at Memorial Sloan Kettering Cancer Center, specializing in urologic oncology with a focus on renal cell carcinoma (RCC). Dr. Hakimi obtained his MD at Albert Einstein College of Medicine and residency at Montefiore Medical Center, culminating in a Urologic Oncology Fellowship at Memorial Sloan Kettering Cancer Center. His research delves



deeply into the tumor microenvironment, immune infiltration, and inflammation in RCC to discover new therapeutic targets. His notable publications include studies on immune checkpoint blockade response and the metabolic landscape of RCC, featured in high-impact journals like *Cancer Cell* and the *Journal of the National Cancer Institute*.

Dr. Hakimi's current projects involve advanced genetic and immunologic methods, including RNA sequencing and flow cytometry, to improve the understanding and treatment of RCC. He has taken a leadership role in the translational kidney cancer program at MSK, co-leading efforts to establish a comprehensive biospecimen bank aimed at personalized disease management. His substantial contributions to the field are supported by his roles in multiple significant research grants from the National Cancer Institute and the Department of Defense.



**Melanie Hawver, MD**  
**Pathologist**  
**Dept: Capital District Pathology Associates**  
**St. Peter's Health Partners**  
**Albany, NY**

Dr. Melanie R. Hawver is a Capital District Pathology Associates partner at St. Peter's Hospital in Albany, NY. She held a previous role as a staff pathologist at Maplewood Pathology. Dr. Hawver completed her medical education at SUNY Upstate Medical University, earning her MD in 2008. Her post-graduate training includes fellowships in Gynecologic Pathology at Weill Cornell Medical College and Surgical Pathology at the Hospital of the University of Pennsylvania, followed by an Anatomic and Clinical Pathology residency at Columbia University Medical Center.

Dr. Hawver's academic contributions include peer-reviewed articles and presentations at pathology conferences. She actively engages in professional communities, serving on the Breast Program Leadership Committee at St. Peter's Hospital.



**Gopa Iyer, MD**  
**Associate Attending Physician**  
**Section Head, Urothelial Carcinoma**  
**Memorial Sloan Kettering Cancer Center**  
**New York, NY**

Dr. Gopakumar Iyer is an Associate Professor and Associate Member in the fields of Medicine and Oncology at Memorial

Sloan Kettering Cancer Center and Weill Cornell Medical College. He earned his MD at Vanderbilt University, followed by a residency at the University of Michigan—Ann Arbor, MI, and a fellowship at Weill Cornell.

Dr. Iyer's research primarily focuses on identifying genetic targets in bladder cancers through advanced sequencing techniques. He contributes extensively to the field through his role as the national PI for several clinical trials, highlighting his pivotal role in oncology advancements. His educational contributions are robust, including numerous didactic and clinical teachings at MSK and beyond.



**James Izzano, MD FACOG**  
**Obstetrician & Gynecologist**  
**Department of OB/GYN**  
**St. Mary's Hospital**  
**Amsterdam, NY**

Dr. James Izzano grew up locally attending Broadalbin-Perth High School and his stomping ground was mostly The Great Sacandaga Lake. He attended the Rochester Institute of Technology completing a bachelor's degree in industrial and systems engineering. An alumnus of Albany Medical College, he completed his residency in obstetrics and gynecology at Dartmouth-Hitchcock Medical Center in New Hampshire. He returned home taking his first job as an attending at St. Mary's Hospital in Amsterdam, NY where he continues to work. This is the same labor and delivery unit in which he and the rest of his family were all born. He is a fellow of the American College of Obstetricians and Gynecologists and resides in Stillwater, NY.



**Justin Juliano, MD**  
**Radiation Oncologist**  
**New York Oncology Hematology**  
**Clifton Park, NY**

Justin Juliano, MD is a board-certified radiation oncologist at New York Oncology Hematology in Clifton Park, NY. He graduated from SUNY Upstate Medical University. He then completed residency at the Cleveland Clinic, where he served as Chief Resident. In his free time, he enjoys spending time with family where he can be found in the ADK skiing or hiking.



**Ellie Kolor, Student**  
**Touro College of Osteopathic Medicine**  
**Middletown, NY**

Ellie Kolor is a medical student pursuing a career as a gynecological oncologist. She graduated with a Bachelor of Science in Biology from Binghamton University and is currently attending Touro College of Osteopathic Medicine. Alongside her academic pursuits, Ellie has extensive experience in the hospitality industry, holding positions as a server at Shadows on the Hudson and Aroma Osteria, and as a manager at Vitality Bowl. Her roles have honed her skills in customer service, team management, and problem-solving. She is adept at enhancing service quality by attentively listening and responding to customer needs, ensuring food safety, and managing HR matters. Ellie's commitment to healthcare and service excellence is further exemplified by her ability to juggle demanding roles while maintaining high standards in both her professional and academic endeavors. Her skills also extend to public speaking, computer science, and creating content for various media platforms, showcasing her versatility and dedication.



**Joshua Kesterson, MD, MBA**  
**Director, Department of Gynecologic Oncology**  
**UPMC-Central PA**  
**Harrisburg, PA**

Dr. Joshua Philip Kesterson is a leading medical professional specializing in Gynecologic Oncology. He is the Medical Director at UPMC Central PA Women's Cancer Center. Dr. Kesterson is also the Chief of Gynecologic Oncology at Penn State Health Milton S. Hershey Medical Center and is an Associate Professor in the Department of Obstetrics and Gynecology. He earned his MD from the University of Missouri-Columbia and an MBA from Penn State University, complementing his extensive training with a residency at the University of Louisville and a fellowship at Roswell Park Cancer Institute.


Dr. Kesterson has contributed to gynecologic oncology through numerous research projects, peer-reviewed publications, and clinical trials, focusing on areas like ovarian cancer chemoresistance and endometrial carcinoma molecular classification. His active participation in professional societies and roles in editorial activities further underline his commitment to advancing his field.



**Thomas Krivak, MD**  
**Director, Division of Gynecologic Oncology**  
**Allegheny Health Network**  
**The Western Pennsylvania Hospital**  
**Pittsburgh, PA**

Dr. Thomas C. Krivak is the director of the division of gynecologic oncology and chief surgeon at Western Pennsylvania Hospital in Pittsburgh. He received his medical degree from Ohio State College of Medicine. His postgraduate training included an obstetrics and gynecology internship and residency at David Grant Medical Center/Travis Air Force Base, followed by a fellowship in gynecologic oncology at Walter Reed Army Medical Center. Dr. Krivak completed a research fellowship in the Department of Cell Biology at the National Cancer Institute in Washington DC.

Dr. Krivak's extensive involvement in gynecologic oncology research is evident in his numerous publications. His academic contributions include numerous peer-reviewed articles focusing on innovative treatments and surgical techniques in gynecologic oncology. Dr. Krivak is an active member of several professional societies, has received several academic and service awards, and continues to contribute to clinical trials and research, underlining his dedication to improving patient outcomes in gynecologic oncology.



**Shashi Lele, M.D.**  
**Chairman Emeritus and Professor of Oncology**  
**Medical Director International Patients**  
**Department of Gynecologic Oncology**  
**Roswell Park Cancer Institute**  
**Buffalo, NY**

Dr. Shashikant B. Lele is the Clinical Chief of Gynecologic Oncology, Clinical Chair of the Division of Surgical Subspecialties, and Clinical Professor of Gynecology and Obstetrics at the Roswell Park Comprehensive Cancer Center in Buffalo, New York. He received his medical degree from Bombay University, India, and his residency training at Mt. Sinai Hospital, Ohio. He further specialized in gynecologic oncology during his fellowship at Roswell Park Cancer Institute.

Dr. Lele has contributed to clinical and research advancements in gynecologic oncology, particularly in surgical procedures and chemotherapy treatments for ovarian and uterine cancers. His research focus on cancer markers and innovative treatment methods has contributed to over 200 publications, enhancing understanding and treatment protocols in ovarian and endometrial cancers.

With a distinguished career spanning several decades, Dr. Lele has held numerous prestigious positions and contributed significantly to the field of gynecologic oncology. His clinical expertise is complemented by extensive involvement in clinical research, teaching, and mentorship.



**Colleen Murray, MSN, RNFA, FNP-C**  
**New York Oncology Hematology**  
**Albany, NY**

Colleen D. Murray, FNP-C, RNFA, has established a career in nursing and specialized healthcare, particularly in oncology and surgical assistance. She is currently a Family Nurse Practitioner at New York Oncology Hematology in Albany. Colleen obtained her BS from The Sage Colleges in 1996 and a MS in Nursing from Sage Graduate School in 2000.

She has obtained several credentials, including Registered Nurse First Assistant (2001), da Vinci Surgical Training

(2005), and a Myriad Certified Genetic Counselor (2000). Her professional experience is rich with roles like Clinical Care Coordinator at St. Peter's Hospital (1996-2000) and Family Nurse Practitioner in various capacities, including GYN Oncology at Women's Cancer Care Associates (2000-2017) and GYN Urology at Trinity Health Care (2008-2018).



**Mary Paquet, FNP-C**  
**Director of Weight Management Services**  
**Elevate Health Associates**  
**Poughkeepsie, NY**

Mary Paquet is a board-certified Family Nurse Practitioner specializing in Obesity Medicine and Metabolic Health. She holds degrees from Stony Brook University and Boston College and has accumulated extensive experience managing obesity through evidence-based medical and nutritional therapies. She practices at Elevate Health Associates and Vassar College in Poughkeepsie, NY, focusing on integrating obesity management with psychiatric care to optimize overall health outcomes. Previously, she served at Northern Dutchess Hospital, specializing in bariatric and metabolic surgery, and at Hudson Valley Primary Care, providing broad primary care services. Paquet's professional affiliations include memberships in the American Association of Nurse Practitioners and the Obesity Medicine Association.



**Rébecca Phaëton, MD**  
**Senior Medical Director, Gynecologic Oncologist**  
**GlaxoSmithKline**  
**Hershey, PA**

Dr. Rébecca Phaëton serves as the Senior Medical Director, Niraparib at GlaxoSmithKline. She earned her MD from the Joan C. Edwards School of Medicine at Marshall University School of Medicine in Huntington, WV, and completed her Obstetrics and Gynecology residency at the Hospital of the University of Pennsylvania, where she also served as the Administrative Chief Resident. Her specialized training



continued with a Gynecologic Oncology Fellowship at Albert Einstein College of Medicine/Montefiore Medical Center and a postdoctoral fellowship in Immunology.

In her administrative roles, Dr. Phaëton has contributed as Co-Director of the Gynecologic Malignancies Group and Assistant Director of Residency Research at Penn State College of Medicine, Hershey PA. Her major academic appointments include positions as an Assistant Professor in the Departments of Obstetrics and Gynecology, and Microbiology and Immunology at Penn State, where she also served on numerous educational and research committees.

Dr. Phaëton's research focuses on cervical cancer immunotherapy and HPV-related cancers. Her significant contributions to the field are evident through her involvement in various clinical trials and research programs, which have advanced our understanding and treatment of these diseases. She is affiliated with the American Association for Cancer Research and the American Society of Clinical Oncology.



**Rahul Ravilla MD MS**  
**Assistant professor of medicine**  
**New York Oncology Hematology**  
**Albany medical center**  
**Albany NY**

Dr. Rahul Ravilla is an Assistant Professor of Medicine at Albany Medical Center and an Attending Physician at New York Oncology Hematology. He obtained his medical degree from Guntur Medical College, NTR University of Health Sciences, Guntur, India. Dr. Ravilla's educational background includes a Clinical Fellowship in Hematology-Oncology and a Master of Science in Clinical and Translational Sciences from the University of Arkansas for Medical Sciences, where he also completed his residency in Internal Medicine. His expertise spans genitourinary cancers, and he serves on the executive committee at the Sarah Cannon Research Institute and as a medical director at Ontada/McKesson Corporation.

Dr. Ravilla has received multiple accolades for his research contributions, including the Conquer Cancer ASCO Foundation Merit Award. His extensive research involvement includes being a principal investigator in several significant clinical trials targeting innovative cancer treatments. He ac-

tively contributes to the medical community through leadership in various research committees and as a reviewer for several esteemed journals. His commitment to medical education and patient care is evident from his numerous presentations at national conferences and his dedication to improving clinical practices and outcomes.



**Danielle Rooney, MD, FACOG**  
**Obstetrician & Gynecologist**  
**Community Care Obstetrics and**  
**Gynecology**  
**Schenectady, NY**

Dr. Danielle Rooney is board certified in obstetrics and gynecology from The American Board of Obstetrics and Gynecology. She received her medical degree from Albany Medical College in Albany, NY, and completed her residency in the department of OB/GYN at Albany Medical College. Dr. Rooney began her studies at the University of Vermont in Burlington, VT, earning a bachelor's degree in medical laboratory science.

Prior to joining Community Care Physicians, Dr. Rooney worked in a private practice that offered obstetrics, gynecology, and midwifery care. She enjoys healthcare because, despite the challenges, frustrations, and sacrifices, she believes it always continues to be a very rewarding profession above all else.

Dr. Rooney chose to specialize in obstetrics and gynecology because she enjoyed the continuity with her patients. She appreciated the relationships you build with patients and being involved in a special event in their lives. Dr. Rooney also enjoys her specialty being a mixture of health maintenance, procedures, and minimally invasive surgery. She enjoys being able to see patients through all stages of their lives and the privilege of being allowed to be involved in very personal and intimate aspects of their lives. Dr. Rooney is a Fellow of the American College of Obstetricians and Gynecologists and a member of the American Society for Colposcopy and Cervical Pathology.

In her spare time, Dr. Rooney enjoys spending time with her family and being outside, skiing in the winter, and boating in the summer. She has two children and two dogs.



**Mark S. Shahin, MD, FCOG, FACS**  
**Chief Surgical Officer & Lead**  
**Gynecologic Oncologist**  
**Alliance Cancer**  
**US Oncology Network**  
**Doylestown, PA**

Mark Shahram Shahin, MD, FCOG, FACS is the Chief Surgical Officer and Lead Gynecologic Oncologist at Alliance Cancer Specialists, at The US Oncology Network. He is a PI with Sarah Cannon Research Institute. He is a professor of OB GYN at the Sidney Kimmel Medical College of Thomas Jefferson University. Over the last decade he served as the Director of the Hanjani Institute for Gynecologic Oncology at Abington Jefferson Hospital and Deputy Director of the Asplundh Cancer Pavilion of Sidney Kimmel Cancer and the enterprise director of Gynecologic Oncology for Jefferson Health.

He received his BS in Bioengineering at Syracuse University, Doctor of Medicine at Northwestern University, performed his residency in Obstetrics and Gynecology at McGaw Medical Center of Northwestern University and completed two fellowships in advanced gynecologic surgery and gynecologic oncology at the University of Iowa Hospitals and Clinics.

His early research focused on p53 genetic mutations in ovarian malignancies and more recently is focused on drug development in phase II and III trials for ovary and endometrial cancer. Dr. Shahin has authored over 40 manuscripts on treatments of gynecologic cancers and is a principal investigator for NRG Oncology

His clinical interest is in cytoreductive surgery of advanced gynecologic cancers and advanced robotic surgery for gynecologic cancers, as well as management of recurrent ovarian cancer. He is a co-chair of the Health Policy Socioeconomic Committee for the Society of Gynecologic Oncology. And also, is co-chair of surgical oncology committee of NRG oncology.



**Susan Slovin, MD, PhD**  
**Associate Vice Chair of Academic**  
**Affairs**  
**Memorial Sloan Kettering Cancer**  
**Center**  
**New York, NY**


Dr. Susan F. Slovin serves as the Associate Vice Chair of Academic Affairs at Memorial Sloan-Kettering Cancer Center (MSKCC). She has a distinguished career in medical oncology, specifically prostate cancer research and treatment. She obtained an M.Phil and Ph.D. in Pathobiology from Columbia University and an MD from Jefferson Medical College.

Dr. Slovin's contributions to medical education and clinical practice are extensive. She has held multiple leadership roles, such as Chair of the Data Safety Monitoring Committee and Vice Chair of the MSK Pediatric Data and Safety Monitoring Committee, as well as numerous other leadership and advisory positions. Her research is well-published, focusing on immunotherapy and targeted therapies for prostate cancer, contributing to significant advancements in the field. Dr. Slovin is an active educator and speaker, involved in many lectures and presentations nationally and internationally, focusing mainly on the treatment and management of prostate cancer.



**Karim A. Touijer, MD, MPH.**  
**Attending Surgeon**  
**Urology Service, Dept. of Surgery**  
**Professor of Urology**  
**Weill Cornell Medical School**  
**New York, NY**

Karim Touijer is an Attending Surgeon at Memorial Sloan-Kettering Cancer and Associate Professor of Urology at The Weill Medical College of Cornell University in New York. Dr Touijer is an expert in the use of advanced laparoscopic/robotic surgical techniques to treat patients with genito-urinary cancers (prostate, kidney, bladder, testis and adrenal cancers). He teaches advanced laparoscopic urologic oncology at the European Association of Urology, the American Urological Association Annual Meetings and the European Institute of Telemedicine. Dr Touijer's research focuses on the development of innovative minimally invasive techniques such as laparoscopy, robotic assisted surgery, and image



guided interventions, the comparison of minimally invasive surgery to conventional open surgery with regards to cancer control and impact on the quality of life, and the implementation of quality outcome metrics to objectively measure and assess surgical performance. His laboratory research focuses on studying lymph node metastases for genitourinary malignancies using cancer targeted nanotechnology probes. After a fellowship in urologic oncology and advanced laparoscopic oncology at MSKCC, he joined the MSKCC Urology faculty in 2004. Dr Toujier is completing a Master's in Public Health from the Harvard School of Public Health. He is board certified by the American Board of Urology, Fellow of the American College of Surgeons and member of the Society of Urologic Oncology, the American Urological Association, the European Association of Urology, the American Society of Clinical Oncology and other national and international societies; additionally he serves on the editorial board and as a reviewer of a number of peer-reviewed urology and cancer journals. Dr Toujier has authored over 100 peer-reviewed journal articles and book chapters. He is the editor of a book chapter on the management of genito-urinary malignancies and a regular visiting professor and guest speaker to numerous meetings and symposia around the world.



**Martin Voss, MD**  
**Associate Member**  
**Dept of Medicine, Memorial Sloan**  
**Kettering Cancer Center**  
**New York, NY**

Dr. Martin Voss is a genitourinary oncologist and an Associate Member at Memorial Sloan Kettering Cancer Center in New York where is a senior member of the Genitourinary Oncology

Service. He is an Associate Professor at Weill Cornell Medical College in New York.

A recognized expert in the field of kidney cancer, Dr. Voss has a long track record drug development in this disease, with leadership roles on multi-center phase I-III trials with industry partners. He has served as study chair for multi-institutional randomized clinical trials, as steering committee member for several international phase 3 studies and as member of data safety monitoring committee in the multi-center setting. Dr. Voss has developed, led, and reported investigator-initiated trials including NCI sponsored work. His trial efforts in orphan indications (papillary and unclassified RCC) led to NCCN endorsement of a dedicated regimen in that indication, providing access to that treatment in an underserved population of patients.

Aside from his work in drug development, Dr. Voss has made serial contributions to biomarker discovery in this disease. In collaborating with basic scientists as well as industry partners, he has generated insights into molecular tools to risk stratify patients and has reported novel ways to characterize the tumor immune microenvironment pointing to novel treatment strategies in the context of postoperative surveillance and metastatic treatment.

He has served as a member of the Society for Immunotherapy of Cancer (SITC) "Kidney Cancer Immunotherapy Guidelines Task Force" and has been a member to the Scientific Advisory Committee of KCCURE and the Kidney Cancer Research Alliance. Dr. Voss has co-authored >130 publications in peer-reviewed journals, including original research published in Nature Genetics, Cancer Cell, Science, Cancer Discovery, Lancet, Lancet Oncology, the Journal of Clinical Oncology, and the New England Journal of Medicine. He is an editorial board member of Clinical Genitourinary Cancer and Kidney Cancer and a contributing author to Harrison's Principles of Internal Medicine.



## HOW TO CLAIM CREDIT

### SIGN IN FOR THE SESSIONS

- Sign in for each session attended

### SCAN THE EVALUATION/CLAIM CREDIT QR CODE

- Complete the evaluation and claim credit



SIGN IN



EVALUATION/CLAIM CREDIT

## ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provider-ship of the Medical Society of the State of New York (MSSNY) and myMedEd, Inc. MSSNY is accredited by the ACCME to provide continuing medical education for physicians.



## CREDIT DESIGNATION STATEMENT

The Medical Society of the State of New York designates this live activity for a maximum of 12.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by

the ACCME, please consult your professional licensing board.

As an ACCME-accredited provider, MSSNY will identify and mitigate relevant financial relationships of all individuals who control CME content.

## ASSURANCE OF BALANCED, UNBIASED, AND FAIR CONTENT

As an ACCME-accredited provider, MSSNY must identify and mitigate relevant financial relationships of all individuals controlling CME content.

Financial relationships are relevant if the following three conditions are met for the prospective person who will control the content of the education:

- A financial relationship, in any amount, exists between the person in control of content and an ineligible company.
- The financial relationship existed during the past 24 months.
- The educational content is related to the products of an ineligible company with whom the person has a financial relationship.

Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/ or investigational use of pharmaceuticals or instruments discussed in their presentation.

## FACULTY & PLANNER DISCLOSURES

To view a list of faculty and planner disclosures, including faculty with relevant financial relationships with ineligible companies, go to: [spring2liferegistration.org](http://spring2liferegistration.org) or scan the QR Code and click on the ACCREDITATION tab.



DISCLOSURES

# Cancer treatment takes a toll. Not just on the body, but on a family's bottom line.

The NYOH Community Cancer Foundation's mission is to provide financial assistance and valuable resources to those diagnosed with cancer.

Be part of our community that's greater than cancer. Donate today!



**NYOH** Community Cancer Foundation

The NYOH Community Cancer Foundation is recognized as a tax-exempt organization under section 501(c)(3) of the Internal Revenue Code, EIN 14-1822194.

[nyohfoundation.org](http://nyohfoundation.org)

**NYOH** New York Oncology Hematology

## Cancer is One Chapter in Your Story.

If you or a loved one find yourself with a cancer diagnosis, the experts at New York Oncology Hematology are here to help you continue to tell your story.

Contact us today to schedule an appointment or for a second opinion.

[newyorkoncology.com](http://newyorkoncology.com)

Albany • Albany Med • Amsterdam • Clifton Park • Hudson • Troy







A new standard in patient-first healthcare: not just being cared for—feeling cared for.

## We do it a little bit different—and we're proud of that

At Akira, patients receive a full suite of medical imaging and support services in an environment designed to take some of the stress out of doing the things needed to do to maintain one's health.

### Advanced Mammography Services

- Offering cutting-edge Hologic 3D mammography technology
- New comfort paddle for enhanced compression tolerance during exams

### Precise Pelvic and Breast Ultrasounds

- Comprehensive breast and pelvic ultrasounds for accurate diagnostics

### Streamlined Breast Biopsies

- Patients benefit from our Hologic Brevera system which means more efficient sampling, allowing for decreased procedure time

### DEXA Bone Density Scans

- Timely patient appointment availability

### Patient-Centric Convenience

- Akira takes care of obtaining prior imaging and reports
- Offering flexible scheduling and convenient walk-in hours
- Prescription-free screening mammograms for those with average risk\*

### Rapid Diagnostic Results

- Same-day diagnostic exam results

*\*Must not have new breast complaints or cancer symptoms, and prior imaging reports must indicate eligibility for annual screening mammograms, excluding those suggesting follow-up imaging, short-term interval exams, or biopsy.*



Questions? Call us at 518 239 5200 or email [hello@akiracares.com](mailto:hello@akiracares.com).

400 Patroon Creek Blvd. Suite 104 • Albany, NY 12206  
p: 518 239 5200 • f: 518 616 7200 • [hello@akiracares.com](mailto:hello@akiracares.com)  
Hours of Operation: Monday – Friday • 7:00 am – 5:00 pm

   @akiracaresNY  
[akiracares.com](http://akiracares.com)



**Optional Non-CME Ancillary Event**  
**Thursday May 2, 2024 – 11:50am to 12:50pm**  
**Level 1 – Meeting Room 1A**

# ***A Different Approach to Treat Metastatic Urothelial Cancer***

**Gilead Sciences, Inc., is proud to present a  
meeting on metastatic urothelial cancer.**

## **Alan Tan, MD**



Dr Tan is Director of Genitourinary Medical Oncology, Assistant Professor of Medicine at Rush University Medical Center, and Co-Chair of the HCRN Melanoma Working Group. He is also the Executive Officer for Genitourinary Oncology Protocols with the Alliance for Clinical Trials in Oncology. He is a member of numerous professional societies, including the American Society of Hematology, American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, among others. Dr Tan led the team that enrolled the first patient worldwide in a phase 3 NKTR-214 PIVOT 09 study. He completed his residency in internal medicine and fellowship in hematology/oncology at the Saint Louis University School of Medicine.

**This activity is supported by**



# Thank you to our Sponsors and Exhibitors:

## PRODUCT THEATER

Gilead Sciences, Inc.

## PLATINUM SPONSORSHIP

Gilead Sciences, Inc.  
Johnson & Johnson Innovative Medicine  
Novartis AG  
Pfizer Inc.

## GOLD SPONSORSHIP

Agios Pharmaceuticals	GSK plc
AstraZeneca	ImmunoGen, Inc.
Bristol Myers Squibb	Merck & Co., Inc.
Eisai Co., Ltd.	Pfizer Inc.
EMD Serano Inc.	Sanofi
Exelixis, Inc.	Takeda Oncology
Genmab US, Inc.	

## SILVER SPONSORSHIP

Incyte Corporation

## BRONZE SPONSORSHIP

AbbVie, Inc.	Lilly USA, LLC.
Adaptive Biotechnologies	Merck & Co., Inc.
Amgen Inc.	Myriad Genetics, Inc.
Astellas Pharma Inc.	NeoGenomics Laboratories
BeiGene, Ltd.	Pharmacosmos Therapeutics, Inc.
Biotheranostics, Inc.	Pharmacyclics LLC
Bristol Myers Squibb	Servier Pharmaceuticals
Daiichi Sankyo, Inc.	Sobi
Ipsen	SpringWorks Therapeutics

*Hosted By*



*Organized By*

